AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8422235 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric currents of 10-20 mA for 10-20 min with 1% mepivacaine or lidocaine with epinephrine
Number of subjects: 28
Study 8422235 — intervention group
Group type: COMPARATOR
Intervention: No drugs or a current of reverse polarity applied
Number of subjects: 28
Study 8422235 — intervention group
Group type: COMPARATOR
Intervention: Electric currents (3.5-5.0 mA) applied for 20 min to 10 solutions in cadaveric bladders
Number of subjects: 28
Study 8422235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionized dyes applied to cadaveric bladders
Number of subjects: 28
Study 2878678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufuralol 7.5 mg
Number of subjects: 8
Study 2878678 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 8
Study 2878678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufuralol 15 mg
Number of subjects: 8
Study 2878678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufuralol 30 mg
Number of subjects: 8
Study 2878678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufuralol 60 mg
Number of subjects: 8
Study 2878678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bufuralol 120 mg
Number of subjects: 8
Study 2878678 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 8
Study 2878678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 29289702 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for dietary self-monitoring
Number of subjects: 0
Study 29289702 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for interim weight loss
Number of subjects: 0
Study 29289702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of financial incentives for dietary self-monitoring and interim weight loss
Number of subjects: 0
Study 29289702 — intervention group
Group type: COMPARATOR
Intervention: No financial incentives for dietary self-monitoring
Number of subjects: 0
Study 29289702 — intervention group
Group type: COMPARATOR
Intervention: No financial incentives for interim weight loss
Number of subjects: 0
Study 29289702 — intervention group
Group type: COMPARATOR
Intervention: No financial incentives for both dietary self-monitoring and interim weight loss
Number of subjects: 0
Study 25780997 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray cryotherapy
Number of subjects: 22
Study 25780997 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study 23157542 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 144
Study 23157542 — intervention group
Group type: EXPERIMENTAL
Intervention: Power-type resistance training (RT)
Number of subjects: 144
Study 23157542 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 144
Study 22291074 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 2616
Study 22291074 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 2616
Study 21533288 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid about bisphosphonates
Number of subjects: 18
Study 21533288 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care (Control)
Number of subjects: 18
Study 20329382 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard MDT + once a month supervised 100 mg of Minocycline and 400 mg of Ofloxacin for 12 months
Number of subjects: 100
Study 16520446 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline past-week depressive symptomatology (dichotomous)
Number of subjects: 1659
Study 16520446 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline past-week depressive symptomatology (continuous)
Number of subjects: 1659
Study 12973820 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release methylphenidate (Ritalin LA) 40 mg administered intact with a high-fat breakfast
Number of subjects: 0
Study 12973820 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified-release methylphenidate (Ritalin LA) 40 mg sprinkled on applesauce
Number of subjects: 0
Study 12973820 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition (control group)
Number of subjects: 0
Study 11885169 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA)‐coated implants
Number of subjects: 0
Study 11885169 — intervention group
Group type: COMPARATOR
Intervention: Non‐coated implants
Number of subjects: 0
Study 11885169 — intervention group
Group type: COMPARATOR
Intervention: Non‐coated implants in bone quality 3
Number of subjects: 0
Study 11885169 — intervention group
Group type: COMPARATOR
Intervention: Non‐coated implants in bone quality 4
Number of subjects: 0
Study 9003951 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% oxatomide gel
Number of subjects: 22
Study 9003951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (petrolatum ointment)
Number of subjects: 22
Study 1510262 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (10 micrograms/m2 of body surface area)
Number of subjects: 30
Study 1510262 — intervention group
Group type: COMPARATOR
Intervention: Physiologic saline solution (placebo group)
Number of subjects: 30
Study 6239548 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia applied to the fallopian tubes
Number of subjects: 300
Study 6239548 — intervention group
Group type: COMPARATOR
Intervention: No topical anesthesia
Number of subjects: 300
Study 31724334 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosialotetrahexosylganglioside (GM1)
Number of subjects: 196
Study 31724334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 30682452 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM) treatment
Number of subjects: 142
Study 30682452 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-gene signature (6GS)
Number of subjects: 142
Study 29071987 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-needle winding and pulling combined with electroacupuncture
Number of subjects: 60
Study 29071987 — intervention group
Group type: COMPARATOR
Intervention: Routine electroacupuncture treatment (Control)
Number of subjects: 60
Study 25833784 — intervention group
Group type: EXPERIMENTAL
Intervention: Mamba (50 g, 260 kcal, >75% of RDA for critical micronutrients)
Number of subjects: 1167
Study 25833784 — intervention group
Group type: COMPARATOR
Intervention: Tablet Yo (42 g, 165 kcal)
Number of subjects: 1167
Study 25833784 — intervention group
Group type: COMPARATOR
Intervention: Control group (unfortified cereal bar)
Number of subjects: 1167
Study 24355804 — intervention group
Group type: EXPERIMENTAL
Intervention: Service-learning environment
Number of subjects: 0
Study 24355804 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21968012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg/day
Number of subjects: 36
Study 21968012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19379470 — intervention group
Group type: EXPERIMENTAL
Intervention: Double kissing (DK) crush stenting technique
Number of subjects: 312
Study 19379470 — intervention group
Group type: COMPARATOR
Intervention: Classical crush stenting technique
Number of subjects: 312
Study 17408017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KTZ) at a 600 mg/day maintenance dose for periods ranging from 15 days to 13 years.
Number of subjects: 54
Study 15008034 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-nurse team
Number of subjects: 2
Study 15008034 — intervention group
Group type: COMPARATOR
Intervention: Physician-only
Number of subjects: 2
Study 11317060 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicines
Number of subjects: 0
Study 11317060 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring and assisting in herbal therapeutic decisions
Number of subjects: 0
Study 11317060 — intervention group
Group type: COMPARATOR
Intervention: Conservative approach against herbal medicine use
Number of subjects: 0
Study 9438684 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin/vinblastine/cisplatin regimen
Number of subjects: 0
Study 9438684 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 0
Study 9438684 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (135 mg/m2 and 250 mg/m2) combined with cisplatin
Number of subjects: 0
Study 9438684 — intervention group
Group type: COMPARATOR
Intervention: Etoposide/cisplatin
Number of subjects: 0
Study 7517829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive drug treatment (combinations of colestipol, nicotinic acid and lovastatin)
Number of subjects: 72
Study 7517829 — intervention group
Group type: COMPARATOR
Intervention: Diet and modest doses of colestipol (Control)
Number of subjects: 72
Study 7517829 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and lovastatin (up to 80 mg daily)
Number of subjects: 72
Study 7517829 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (Control)
Number of subjects: 72
Study 7517829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive drug treatment (in women)
Number of subjects: 72
Study 7517829 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (in men) (Control)
Number of subjects: 72
Study 7517829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive drug treatment (in men)
Number of subjects: 72
Study 3139326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (NG) therapy
Number of subjects: 310
Study 31777235 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-time electroacupuncture treatment (once a day for 5 times)
Number of subjects: 60
Study 31777235 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-time electroacupuncture treatment (once a day for 10 times)
Number of subjects: 60
Study 31777235 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 5-time and 10-time treatment groups
Number of subjects: 60
Study 28502496 — intervention group
Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg omega-3 fatty acids EE) under fasted conditions
Number of subjects: 24
Study 28502496 — intervention group
Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg omega-3 fatty acids EE) under low-fat meal conditions
Number of subjects: 24
Study 28502496 — intervention group
Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg omega-3 fatty acids EE) under high-fat meal conditions
Number of subjects: 24
Study 28502496 — intervention group
Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg omega-3 fatty acids EE) under low-fat/high-fat meal conditions
Number of subjects: 24
Study 28502496 — intervention group
Group type: EXPERIMENTAL
Intervention: SC401 (1530 mg omega-3 fatty acids EE)
Number of subjects: 24
Study 24957913 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) applied to the common fibular nerve during surgery
Number of subjects: 90
Study 24957913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electrical stimulation)
Number of subjects: 90
Study 23124244 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium species (B. adolescentis, B. bifidum, B. dentium, B. breve, B. longum)
Number of subjects: 87
Study 23124244 — intervention group
Group type: EXPERIMENTAL
Intervention: B. longum
Number of subjects: 87
Study 20851929 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN-RSV01 (0.6 mg/kg)
Number of subjects: 24
Study 20851929 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN-RSV01
Number of subjects: 24
Study 20851929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19357741 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with radiotherapy (CT/RT)
Number of subjects: 80
Study 19357741 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (RT)
Number of subjects: 80
Study 17163253 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus ginger
Number of subjects: 120
Study 17163253 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone
Number of subjects: 120
Study 14644393 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/day for 8 weeks)
Number of subjects: 29
Study 10770982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant 10 mg
Number of subjects: 112
Study 10770982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant 15 mg
Number of subjects: 112
Study 10770982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant 20 mg
Number of subjects: 112
Study 10770982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 9384476 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose therapy and autologous stem cell transplantation
Number of subjects: 139
Study 9384476 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose salvage therapy prior to high-dose therapy
Number of subjects: 139
Study 9796516 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisive nerve block
Number of subjects: 40
Study 9796516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination inferior alveolar nerve block plus incisive nerve block
Number of subjects: 40
Study 9796516 — intervention group
Group type: COMPARATOR
Intervention: Conventional inferior alveolar nerve block
Number of subjects: 40
Study 9796516 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 4010949 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 150 mg
Number of subjects: 59
Study 4010949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 31348349 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand therapy (supervised sessions and home exercises); mean 9.2 sessions over 14.2 weeks
Number of subjects: 0
Study 31348349 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 0
Study 31348349 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand therapy (shorter duration)
Number of subjects: 0
Study 28760939 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (<120 mmHg)
Number of subjects: 7879
Study 28760939 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (<140 mmHg)
Number of subjects: 7879
Study 28760939 — intervention group
Group type: EXPERIMENTAL
Intervention: OBPV overall
Number of subjects: 7879
Study 28760939 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretics or dihydropyridine calcium channel blockers
Number of subjects: 7879
Study 28760939 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers
Number of subjects: 7879
Study 28760939 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite endpoint of fatal and nonfatal cardiovascular events
Number of subjects: 7879
Study 28760939 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure or stroke
Number of subjects: 7879
Study 27983572 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 µg daily for six weeks)
Number of subjects: 76
Study 24583055 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance-guided fluid management
Number of subjects: 131
Study 24583055 — intervention group
Group type: COMPARATOR
Intervention: Clinical judgment without bioimpedance measures
Number of subjects: 131
Study 22665533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² load then 250 mg/m² per week IV)
Number of subjects: 102
Study 22665533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus carboplatin (area under the curve of 2, once per week IV) after progression
Number of subjects: 102
Study 22665533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus carboplatin from the beginning
Number of subjects: 102
Study 22665533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus carboplatin
Number of subjects: 102
Study 19570717 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonabersat 40 mg once daily
Number of subjects: 39
Study 19570717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16709320 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac (100 mg twice daily)
Number of subjects: 247
Study 16709320 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (75 mg twice daily)
Number of subjects: 247
Study 12738704 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions to support implementation of guidelines
Number of subjects: 120
Study 12738704 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fee for telephone consultations
Number of subjects: 120
Study 12738704 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support
Number of subjects: 120
Study 12738704 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular meetings to discuss guidelines
Number of subjects: 120
Study 12738704 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal communication and telephone routines
Number of subjects: 120
Study 10893353 — intervention group
Group type: COMPARATOR
Intervention: External high-frequency oscillation (EHFO)
Number of subjects: 70
Study 10893353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent negative pressure ventilation (INPV)
Number of subjects: 70
Study 9112295 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 786
Study 9112295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 786
Study 1546834 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled indomethacin (2 ml, 1.2 micrograms/ml) three times a day for 14 days
Number of subjects: 0
Study 1546834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3986859 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 9
Study 3986859 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 9
Study 3986859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31412955 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-03 (camostat mesilate) administered three times daily at doses of 100, 200, or 300 mg for 28 days
Number of subjects: 0
Study 31412955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31412955 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-03 (camostat mesilate)
Number of subjects: 0
Study 29224502 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD)
Number of subjects: 1334
Study 29224502 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
Number of subjects: 1334
Study 27002665 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound (US) group; 3 MHz, 1.5 W/cm2
Number of subjects: 50
Study 27002665 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound group
Number of subjects: 50
Study 27002665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TENS + exercise program)
Number of subjects: 50
Study 24071031 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BPAP)
Number of subjects: 27
Study 24071031 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 27
Study 22453316 — intervention group
Group type: EXPERIMENTAL
Intervention: Docusate sodium plus Miralax, fiber wafers, and bisacodyl suppositories
Number of subjects: 60
Study 22453316 — intervention group
Group type: COMPARATOR
Intervention: Docusate sodium
Number of subjects: 60
Study 20233853 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation for 7.3 years
Number of subjects: 3355
Study 18821454 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 6
Study 16015082 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Transplantation
Number of subjects: 30
Study 16015082 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (tarsorrhaphy and bandage contact lens)
Number of subjects: 30
Study 12454554 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI400
Number of subjects: 319
Study 12454554 — intervention group
Group type: EXPERIMENTAL
Intervention: AMI800
Number of subjects: 319
Study 12454554 — intervention group
Group type: COMPARATOR
Intervention: AMI100
Number of subjects: 319
Study 12454554 — intervention group
Group type: COMPARATOR
Intervention: HAL16
Number of subjects: 319
Study 10613592 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO plus G-CSF combination after PBPCT
Number of subjects: 11
Study 8600497 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (150 mg/d)
Number of subjects: 39
Study 8600497 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (2,000 mg/d)
Number of subjects: 39
Study 2007941 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone, 50 mg/kg per day for 5 days
Number of subjects: 40
Study 2007941 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin, 100 mg/kg per day for 5 days
Number of subjects: 40
Study 7102737 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Organizer with written presentation
Number of subjects: 96
Study 7102737 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Organizer with oral presentation
Number of subjects: 96
Study 7102737 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional introduction with written presentation
Number of subjects: 96
Study 7102737 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional introduction with oral presentation
Number of subjects: 96
Study 7102737 — intervention group
Group type: EXPERIMENTAL
Intervention: No introduction with written presentation
Number of subjects: 96
Study 7102737 — intervention group
Group type: EXPERIMENTAL
Intervention: No introduction with oral presentation
Number of subjects: 96
Study 30589567 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening executive functions through group games (12 sessions of 45 minutes each)
Number of subjects: 30
Study 30589567 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 28831548 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) 50 mg/day oral, increased to 2-3 mg/kg/day with oral prednisolone as adjunctive therapy
Number of subjects: 68
Study 28831548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RIT) 1 g intravenous, repeated 2 weeks later and then every 6 months
Number of subjects: 68
Study 28831548 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (RIT)
Number of subjects: 68